Bayer HealthCare reports positive Xarelto data for ACS

Bayer HealthCare has published new clinical data that demonstrates the survival benefits its drug Xarelto can provide to acute coronary syndrome (ACS) patients.

Data from a major subgroup analysis from the Atlas ACS 2-TIMI 51 study showed that ACS patients that had experienced a recent ST-segment elevation myocardial infarction (STEMI) saw a significant mortality benefit when Xarelto was added to standard antiplatelet therapy.

It was also shown that the rivaroxaban-based therapy did not increase the risk of fatal bleeding compared to standard treatment.

Dr Kemal Malik, member of the Bayer HealthCare executive committee and head of global development, said: "This STEMI analysis presents further evidence from the Atlas study that rivaroxaban can significantly improve the care of ACS patients and, most importantly, save lives."

This comes after the company received a recommendation from the National Institute for Health and Clinical Excellence for Xarelto to be approved for use among NHS deep vein thrombosis patients.